Danish Insurance Stock News

Zealand Pharma and Roche have advanced obesity candidate petrelintide into Phase 3 development. Boehringer Ingelheim reported positive Phase III results for obesity drug survodutide, co-invented with Zealand Pharma. Zealand Pharma is eligible for milestone payments and royalties from survodutide, subject to future sales. CPSE:ZEAL is trading at DKK309.0, with the stock down 32.8% year to date and 36.4% over the past 12 months, alongside gains of 39.1% over three years and 57.4% over five...

Recent share moves and business scale Alm. Brand (CPSE:ALMB) has seen mixed returns recently, with the share up 2.9% over the past day but showing declines over the past week, month, and past 3 months. Over longer periods, the stock has delivered a 3.5% 1 year total return and a 44.2% 3 year total return, giving investors context for the recent pullback. The company reported revenue of DKK 13.8b and net income of DKK 1.2b, with both revenue and net income showing annual growth, which helps...

Service resumption to Jersey puts DFDS (CPSE:DFDS) operations back in focus DFDS (CPSE:DFDS) has fully resumed passenger and freight links to Jersey after earlier disruptions from a berthing accident and an engine room fire, and has also announced extra summer day-trips between Jersey and France. See our latest analysis for DFDS. Investors appear to be reassessing DFDS after these operational setbacks were addressed, with a 30 day share price return of 32.51% and year to date gain of 46.85%...

Why Demant Is Back on Value Investors’ Radar Demant (CPSE:DEMANT) has drawn fresh attention after a recent analysis placed it among the most undervalued European stocks, pointing to a sizeable discount to estimated fair value based on discounted cash flows. See our latest analysis for Demant. At a share price of DKK209.0, Demant has seen a 6.85% 1 month share price return. However, the 1 year total shareholder return of 15.79% and 5 year total shareholder return of 35.49% indicate longer term...

The quarterly results for Danske Bank A/S ( CPH:DANSKE ) were released last week, making it a good time to revisit its...

Aktieselskabet Schouw (CPSE:SCHO) has opened Q1 2026 reporting season with mixed trailing numbers, with Q4 2025 revenue of DKK 8.5b and a basic EPS loss of DKK 2.28 against a prior year Q4 EPS of DKK 9.49 on revenue of DKK 8.5b. Over recent quarters, revenue has moved between DKK 7.9b and DKK 9.5b while quarterly EPS has ranged from DKK 4.96 to DKK 15.53 before the latest loss, setting a varied backdrop for how you read this new update. With trailing net margin sitting at 1.9% versus 2.7% a...

Nouvo Nordisk (CPSE:NOVO B) is back in focus after the US rollout of its oral Ozempic tablet, broader GLP-1 access through partnerships with WW International and GoodRx, and an FDA proposal that would curb compounded semaglutide competitors. See our latest analysis for Novo Nordisk. Despite the positive news on oral Ozempic access and supportive FDA signals on compounded GLP 1 competitors, the share price tells a mixed story. A 17.35% 1 month share price return contrasts with a 15.82% year to...

Ørsted (CPSE:ORSTED) has drawn fresh attention after recent share price moves, with the stock showing a mix of shorter term gains and longer term declines that raise questions about how investors are currently valuing its renewable energy business. See our latest analysis for Ørsted. At a latest share price of DKK170.0, Ørsted shows a 90 day share price return of 20.06% and a year to date share price return of 32.81%, while the 3 year total shareholder return of 51.51% and 5 year total...

Brødrene A & O Johansen (CPSE:AOJ B) has opened 2026 with investors focused on how its recent run of quarterly numbers, including Q4 2025 revenue of DKK 1.7 billion, basic EPS of DKK 2.96 and trailing 12 month EPS of DKK 7.37, lines up with a share price sitting at DKK 92. Over the past year, the company has seen total revenue step from DKK 5.4 billion in the 12 months to Q4 2024 to DKK 6.1 billion in the 12 months to Q4 2025. Net income excluding extra items moved from DKK 163.4 million to...

Expanded UK hospital contract shifts attention to ISS (CPSE:ISS) ISS (CPSE:ISS) has expanded its agreement with the Fulham Road Collaborative in the UK, adding a DKK 100 million per year, five-year facility services contract across three major hospital sites. See our latest analysis for ISS. The expanded UK hospital contract arrives while ISS shares trade at DKK238.6, with a 7 day share price return of 4.56% and year to date share price return of 10.67%, alongside a 1 year total shareholder...

Coloplast (CPSE:COLO B) has come back into focus after Biatain Silicone Fit received an Innovative Technology contract from Vizient in the US, shortly after the company lowered its earnings guidance for 2025/26. See our latest analysis for Coloplast. Coloplast shares trade at DKK402.8 after a 1 day share price return of 2.26%. However, the 30 day share price return of 9.03% decline and 1 year total shareholder return of 39.94% decline indicate that momentum has been weak despite the recent...

DSV A/S ( CPH:DSV ) shareholders are probably feeling a little disappointed, since its shares fell 6.4% to kr.1,571 in...

Recent geopolitical tensions that earlier led to the closure of the Strait of Hormuz and instability in the Red Sea have forced container carriers such as A.P. Møller - Mærsk to reroute traffic, turning Africa and ports like Saudi Arabia’s Jeddah into new hubs amid longer transit times and congestion. This reshaping of trade lanes underlines how regional ports such as Sohar, Khorfakkan, Fujairah and Jeddah can quickly gain influence when core shipping corridors are disrupted. We’ll now...

While HusCompagniet A/S ( CPH:HUSCO ) might not have the largest market cap around , it received a lot of attention...

ALK-Abelló (CPSE:ALK B) reported positive topline phase 2 results for its once daily sublingual immunotherapy tablet targeting peanut allergy. The trial results indicated clinically meaningful efficacy and a favorable safety profile across a broad age range of participants. This peanut allergy candidate expands ALK-Abelló’s pipeline beyond its existing allergy tablet portfolio. For investors tracking ALK-Abelló, the phase 2 readout arrives with the share price at DKK242.0 and a 1 year...

Novo Nordisk has launched an oral version of Ozempic across the US, moving its GLP-1 franchise beyond injectable formats. The pill is being rolled out through more than 70,000 pharmacies, along with telehealth, GoodRx, and Weight Watchers partnerships. This broader distribution approach is intended to widen patient access and adjust the company’s GLP-1 strategy in response to competitive and regulatory pressures. Novo Nordisk, traded as CPSE:NOVO B, now has this new oral Ozempic launch...

How AL Sydbank’s recent return profile looks after a strong year AL Sydbank (CPSE:ALSYDB) has drawn attention after a solid 1 year total return of 33.5%, set against mixed shorter term moves. These include a monthly gain of 2.4% and a decline of 3.9% over the past 3 months. See our latest analysis for AL Sydbank. At a share price of DKK549.0, recent trading suggests momentum has cooled in the short term, even as longer term total shareholder returns remain strong. This can reflect shifting...

As of late April 2026, European markets have been navigating a challenging landscape marked by geopolitical tensions and fluctuating economic indicators. Despite these hurdles, opportunities abound for investors willing to explore beyond the mainstream indices. Penny stocks, though often considered niche investments, can offer intriguing growth potential when they are backed by sound financial fundamentals. In this article, we will examine three European penny stocks that stand out for their...

Danske Bank (CPSE:DANSKE) has opened Q1 2026 earnings season with Q4 2025 revenue of DKK 15.2b and basic EPS of DKK 7.72, set against trailing 12 month EPS of DKK 27.94 and revenue of DKK 56.5b and a reported decline in earnings over the last year following several years of strong average growth. Over recent quarters, revenue has moved from DKK 14.7b in Q4 2024 to DKK 15.2b in Q4 2025, while quarterly EPS has ranged between DKK 6.56 and DKK 7.72 as trailing net profit margin eased from 41.5%...

Why the Supreme Court ruling matters for Tryg The Danish Supreme Court’s new workers’ compensation ruling has put Tryg (CPSE:TRYG) in focus as the insurer recognises a one off DKK 1.2b pre tax impact tied to historical cases. At the same time, Tryg and the Danish Insurance Association expect the Danish State to indemnify the industry for this loss. This is a key point for investors weighing legal risk against the insurer’s capital position. See our latest analysis for Tryg. Tryg’s share price...

Alm. Brand Q1 2026 earnings snapshot Alm. Brand (CPSE:ALMB) has followed up its recent Q4 2025 result with total revenue of DKK 3.98b and basic EPS of DKK 0.23, supported over the last 12 months by a net profit margin of 8.2% versus 5.7% in the prior period. Over recent quarters the company has seen revenue range between DKK 3.26b and DKK 3.98b, while quarterly basic EPS has moved between DKK 0.11 and DKK 0.23, alongside trailing EPS growth of 49.3% year over year. Taken together, these...

DSV (CPSE:DSV) opened 2026 with Q1 results anchored by prior quarter revenue of about DKK71.7b and basic EPS of DKK4.72, set against trailing 12 month revenue of roughly DKK247.3b and EPS of DKK35.57. Over recent quarters, revenue has moved from about DKK43.5b in Q4 2024 to the DKK71.7b level in Q4 2025, while quarterly EPS shifted from DKK9.46 to DKK4.72, leaving investors focused on how much of the top line is converting into sustainable margins. See our full analysis for DSV. With the...

Ringkjøbing Landbobank (CPSE:RILBA) has put up another solid scorecard, with trailing twelve month revenue of DKK4.2b and basic EPS of DKK92.86 framing the latest Q1 2026 update, while reported net profit margin sits at 55.7% versus 55.6% a year earlier. Over recent quarters, the bank has seen quarterly revenue move in a tight band between DKK1,003.19m and DKK1,073.47m and basic EPS range from DKK20.68 to DKK23.87, giving investors a clear earnings profile supported by firm margins rather...

Embla Medical hf (CPSE:EMBLA) has opened 2026 with Q1 revenue of US$232.4 million and basic EPS of US$0.034, setting the tone for how its earnings story is evolving against a current share price of DKK26.9. Over the past year, the company has seen trailing twelve month revenue move from US$854.9 million to US$958.3 million while basic EPS on the same basis went from US$0.160 to US$0.202. This gives investors a clearer view of how the top and bottom lines are tracking into this latest quarter...